Vascular Biogenics Ltd. (VBLT) Shares Down 2.8%
Vascular Biogenics Ltd. (NASDAQ:VBLT) shares traded down 2.8% on Monday . The company traded as low as $4.12 and last traded at $4.14, with a volume of 121,924 shares changing hands. The stock had previously closed at $4.26.
A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Thursday, July 14th. HC Wainwright assumed coverage on shares of Vascular Biogenics in a report on Tuesday, June 28th. They issued a “buy” rating and a $11.00 price objective for the company. Roth Capital reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Vascular Biogenics in a report on Thursday, June 9th. Chardan Capital reissued a “buy” rating on shares of Vascular Biogenics in a research note on Tuesday, June 7th. Finally, Piper Jaffray Cos. reissued a “buy” rating and set a $14.00 target price on shares of Vascular Biogenics in a research note on Tuesday, June 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $16.50.
The stock’s market cap is $93.28 million. The firm’s 50-day moving average is $4.11 and its 200-day moving average is $3.64.
Vascular Biogenics (NASDAQ:VBLT) last released its earnings results on Friday, May 13th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.21). Equities research analysts predict that Vascular Biogenics Ltd. will post ($0.82) earnings per share for the current fiscal year.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.